|
|
|
|
LEADER |
03206nam a2200697 4500 |
001 |
ocn757827332 |
003 |
OCoLC |
005 |
20170124070638.9 |
006 |
m o d |
007 |
cr |n||||||||| |
008 |
111017s2011 njuaf ob 001 0 eng d |
040 |
|
|
|a YDXCP
|b eng
|e pn
|c YDXCP
|d UIU
|d E7B
|d N$T
|d TEF
|d OCLCQ
|d NLGGC
|d DEBSZ
|d MHW
|d UKDOC
|d OCLCQ
|d COO
|d OCLCQ
|d GrThAP
|
019 |
|
|
|a 811493902
|a 961689382
|a 962723516
|
020 |
|
|
|a 9781118015377
|q (electronic bk.)
|
020 |
|
|
|a 1118015371
|q (electronic bk.)
|
020 |
|
|
|a 9781118015353
|q (electronic bk.)
|
020 |
|
|
|a 1118015355
|q (electronic bk.)
|
020 |
|
|
|z 9780470184745
|q (cloth)
|
020 |
|
|
|z 0470184744
|q (cloth)
|
020 |
|
|
|z 9781118015360
|
024 |
7 |
|
|a 10.1002/9781118015377
|2 doi
|
029 |
1 |
|
|a AU@
|b 000053283776
|
029 |
1 |
|
|a DEBSZ
|b 430992017
|
029 |
1 |
|
|a DKDLA
|b 820120-katalog:000582681
|
029 |
1 |
|
|a NZ1
|b 14692240
|
029 |
1 |
|
|a DEBBG
|b BV043393613
|
035 |
|
|
|a (OCoLC)757827332
|z (OCoLC)811493902
|z (OCoLC)961689382
|z (OCoLC)962723516
|
050 |
|
4 |
|a QR201.A37
|b H547 2011eb
|
060 |
|
4 |
|a QV 268.5
|
072 |
|
7 |
|a HEA
|x 039020
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 022020
|2 bisacsh
|
082 |
0 |
4 |
|a 616.97/9201
|2 22
|
049 |
|
|
|a MAIN
|
245 |
0 |
0 |
|a HIV-1 integrase :
|b mechanism and inhibitor design /
|c [edited] by Nouri Neamati.
|
264 |
|
1 |
|a Hoboken, N.J. :
|b Wiley,
|c [2011]
|
264 |
|
4 |
|c ©2011
|
300 |
|
|
|a 1 online resource (xiii, 506 pages, [16] pages of plates) :
|b illustrations (some color).
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Wiley series in drug discovery and development
|
588 |
0 |
|
|a Print version record.
|
504 |
|
|
|a Includes bibliographical references and index.
|
520 |
|
|
|a This book comprehensively covers the mechanisms of action and inhibitor design for HIV-1 integrase. It serves as a resource for scientists facing challenging drug design issues and researchers in antiviral drug discovery. Despite numerous review articles and isolated book chapters dealing with HIV-1 integrase, there has not been a single source for those working to devise anti-AIDS drugs against this promising target. But this book fills that gap and offers a valuable introduction to the field for the interdisciplinary scientists who will need to work together to design drugs that target HIV-1.
|
650 |
|
0 |
|a HIV (Viruses)
|x Enzymes.
|
650 |
|
0 |
|a HIV (Viruses)
|x Enzymes
|x Inhibitors.
|
650 |
|
0 |
|a Antiviral agents.
|
650 |
|
2 |
|a HIV Integrase Inhibitors
|x pharmacology.
|
650 |
|
2 |
|a Drug Design.
|
650 |
|
2 |
|a HIV Integrase.
|
650 |
|
4 |
|a Antiviral agents.
|
650 |
|
4 |
|a HIV (Viruses)
|x Enzymes
|x Inhibitors.
|
650 |
|
4 |
|a HIV (Viruses)
|x Enzymes.
|
650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x AIDS & HIV.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x AIDS & HIV.
|2 bisacsh
|
655 |
|
4 |
|a Electronic books.
|
700 |
1 |
|
|a Neamati, Nouri.
|4 edt
|
776 |
0 |
8 |
|i Print version:
|t HIV-1 integrase.
|d Hoboken, N.J. : Wiley, ©2011
|z 9780470184745
|z 0470184744
|w (DLC) 2010043285
|w (OCoLC)670176130
|
830 |
|
0 |
|a Wiley series in drug discovery and development.
|
856 |
4 |
0 |
|u https://doi.org/10.1002/9781118015377
|z Full Text via HEAL-Link
|
994 |
|
|
|a 92
|b DG1
|